Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Inclusion Criteria: * Men and women, ages \>18 * Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL * Provide written informed consent and authorization for protected health information disclosure Exclusion Criteria: * Women who are pregnant or lactating, or planning to become pregnant * Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects * History of pancreatitis * History of bariatric surgery or currently on weight loss drugs * Uncontrolled hypertension (BP \> 160/100) * HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin * Consumption of more than 2 alcoholic beverages per day * History of cancers (except if been disease free for \>5 years OR history was basal or squamous cell skin cancer) * Participation in another clinical trial involving an investigational agent in the last 30 days * Other parameters will be assessed at the study center to ensure eligibility for this study.